Overview

A Study of Inotuzumab and Blinatumomab in People With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

Status:
NOT_YET_RECRUITING
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
Phase:
PHASE2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Amgen
Pfizer
Treatments:
blinatumomab